Tag: Biotech and Pharma

Eli Lilly(LLY) stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday.

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.

Novo Nordisk(NVO) vowed to cut costs Wednesday amid intensifying competition and a cratering stock price as it reported second-quarter earnings.

Pfizer(PFE) raised its full-year earnings guidance as the drugmaker reported quarterly results way ahead of expectations early Tuesday, sending shares of the drugmaker up in premarket trading.

BioNTech(BNTX) stock was rising after the drugmaker reported better-than-expected results early Monday. The company’s second-quarter loss came in at 1.60 euros per share on revenue of €261 million, beating analysts’ expectations of a loss per share of €2.28 on revenue of €151 million, according to FactSet.

President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.

A drug trial failure this spring has had no impact on the market for one of Bristol Myers Squibb’s (BMY) most closely-watched new medicines, the company’s chief commercialization officer, Adam Lenkowsky, told Barron’s ahead of the company’s earnings release Thursday.

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s older diabetes treatment, Trulicity.

AstraZeneca (AZN.L), on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from Washington.

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its blockbuster Wegovy obesity drug in the key U.S. market.

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline.

AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs.

Biogen will invest an additional $2 billion in its existing manufacturing in North Carolina, the drugmaker said on Monday, as it seeks to expand its presence in the U.S. amid President Donald Trump’s tariff threats.

GSK (GSK.L), shares fell more than 6% on Friday to the bottom of Britain’s blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects.

Abbott (ABT.N), beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.

MiNK Therapeutics, Inc. (NASDAQ:INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its allogeneic iNKT cell therapy, agenT-797.

Merck will buy UK-based Verona Pharma (NASDAQ:VRNA) for about $10 billion, the companies said on Wednesday, strengthening the U.S. drugmaker’s respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer treatment.

Novartis (NOVN.S), said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies and very young children.

 Eli Lilly (LLY.N), said on Thursday that India’s drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk’s recently launched Wegovy.